Patients with metastatic prostate cancer who received a vaccine engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, according to researchers at Dana-Farber Cancer Institute, Boston and affiliated organizations.
Patients with metastatic prostate cancer who received a vaccine engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, according to researchers at Dana-Farber Cancer Institute, Boston and affiliated organizations.
The randomized phase II study, published online in the Journal of Clinical Oncology (Jan. 25, 2010), involved the PROSTVAC-VF vaccine, a combination of two weakened poxviruses that have been genetically programmed to produce slightly irregular versions of PSA and three costimulatory molecules that spur the immune system to a more vigorous attack on tumor cells.
The double-blinded trial included 125 patients with metastatic prostate cancer who did not respond to standard, hormone-lowering therapy. Eighty-two of the participants received the vaccine and 40 received placebo.
After 3 years, 30% of the PROSTVAC-VF patients were alive versus 17% of the control group. The median survival of the vaccine group was 24.5 months, compared with 16 months for the control group, an 8.5-month increase. Patients tolerated the vaccine well; only a small number experienced side effects such as fatigue, fevers, and nausea.
"Although this study is relatively small, it offers encouraging evidence of a clinically meaningful benefit from this vaccine approach," said principal investigator and lead author Philip Kantoff, MD, of Dana-Farber Cancer Institute.
Investigators are planning a phase III trial that will enroll about 600 patients to further evaluate the vaccine’s effectiveness.
Malpractice Consult: How likely are you to face a medical malpractice lawsuit?
July 23rd 2024"Although there is a good chance that you will face allegations of medical negligence at some point in your career, it is unlikely that you will ever be found liable by a jury," writes Victoria L. Neikam, Esq.
UK study of AI-based software for prostate cancer detection expands
July 22nd 2024"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and patients, and looking at the impact on workflow," says Clare Verrill, BM, FRCPath, MMedEd.